Mesothelioma of Pleura - Malignant Pericardial Mesotheliomas

References

1. Adams VI, Unni KK, Muhn JR, et al. Diffuse malignant mesothelioma of pleura.
Diagnosis and survival in 92 cases. Cancer 1986;58:1540.
2. Alberts AS, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: a disease
unaffected by current therapeutic maneuvers. J Clin Oncol 1988;6:527.
3. Alberts AS, Falkson G, Zyl LV. Malignant pleural mesothelioma: phase II pilot study
of ifosfamide and mesna. J Natl Cancer Inst 1988;80:698.
4. Allen KB, Faber LB, Warren WH. Malignant pleural mesothelioma. Extrapleural
pneumonectomy and pleurectomy. Chest Surg Clin North Am 1994;4:113.
5. Amato DA, Borden EC, Shiraki M, et al. Evaluation of bleomycin, chlorozotocin,
MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma,
or mesothelioma. Invest New Drugs 1985;3:397.
5a. Andersen MK, Krarup-Hansen A, Martensson G, et al. Ifosfamide in malignant
mesothelioma. A phase II study. Lung Cancer 1999;24:39.
Jr, S Hellman, SA Rosenberg, editors. Cancer. Principles and practice of oncology,
3rd ed. Philadelphia, PA: JB Lippincott; 1989. p. 1399.
6. Anderson H, Hasleton P, Michie AB, et al. 24-hour cyclophosphamide infusion
therapy for malignant mesothelioma of the pleura. Br J Dis Chest 1988;82:64.
7. Anderson HA, Lilis R, Daum SM, et al. Household-contact asbestos: neoplastic
risk. Ann NY Acad Sci 1976;271:311.
8. Antman K, Cohen S, Dimitrov NV, et al. Malignant mesothelioma of the tunica
vaginalis testis. J Clin Oncol 1984;3:447.
9. Antman K, Klegar KL, Pomfret EA, et al. Early peritoneal mesothelioma: a treatable
malignancy. Lancet 1985;2:977.
10. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma. Prognostic variables
in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and
Women's Hospital experience over two decades 1965-1985. J Clin Oncol 1988;
6:147.
11. Antman KH, Blum RH, Greenberger JS, et al. Multimodality therapy for malignant
mesothelioma based on a study of natural history. Am J Med 1980;68:356.
12. Antman KH, Pass HI, Recht A. Benign and malignant mesothelioma. In: VT DeVita

13. Antman KH, Pomfret EA, Aisner J, et al. Peritoneal mesothelioma. Natural history
and response to chemotherapy. J Clin Oncol 1983;1:386.
14. Appel JD, Fasy TM, Kohtz DS, et al. Asbestos fibers mediate transformation of monkey
cells by exogenous plasmid DNA. Proc Natl Acad Sci USA 1988;85:7670.
15. Ardizzoni A, Rosso R, Salvati F, et al. Activity of doxorubicin and cisplatin combination
chemotherapy in patients with diffuse malignant pleural mesothelioma. An
Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 1991;67:2984.
16. Ashcroft T. Epidemiological and quantitative relationships between mesothelioma
and asbestos on Tyneside. J Clin Pathol 1973;26:832.
16a. Astoul P, Picat-Joossen D, Viallat JR, Boutin C. Intrapleural administration of interleukin-
2 for the treatment of patients with malignant pleural mesothelioma: a
phase II study. Cancer 1998;83:2099.
17. Auerbach O, Conston AS, Garfinkel L, et al. Presence of asbestos bodies in organs
other than the lung. Chest 1980;77:133.
18. Ayres JG, Crocker JG, Skilbeck NQ. Differentiation of malignant from normal and
reactive mesothelial cells by the argyrophil technique for nucleolar organiser
region associated proteins. Thorax 1988;43:366.
19. Bajorin D, Kelsen D, Mintzer DM. Phase II trial of mitomycin in malignant
mesothelioma. Cancer Treat Rep 1987;71:857.
19a. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy
for malignant pleural mesothelioma. Ann Thorac Surg 1997; 63:334.
20. Bamler KJ, Maassen W. Malignen pleuramesothelioms. Thoraxchir 1974;22:386.
21. Baris YI, Artvinli M, Sahin AA. Environmental mesothelioma in Turkey. Ann NY
Acad Sci 1979;330:423.
22. Baris YI, Saracci R, Simonato L, et al. Malignant mesothelioma and radiological
chest abnormalities in two villages in central Turkey. An epidemiological and
environmental investigation. Lancet 1981;1:984.
23. Barrett JC, Lamb PW, Wiseman RW. Multiple mechanisms for the carcinogenic
effects of asbestos and other mineral fibers. Environ Health Perspect 1989;81:81.
23a. Bavisetto LM, Rankin C, Behrens BC, et al. A phase II Southwest Oncology Group
study of dihydroxyazacytidine for mesothelioma. Cancer Ther 1998;1:18.
23b. Beattie JE. The treatment of malignant pleural effusions by partial pleurectomy.
Surg Clin North Am 1963;43:99.
24. Beck B, Konetzke G, Ludwig V, et al. Malignant pericardial mesotheliomas and
asbestos exposure: a case report. Am J Indust Med 1982;3:149.
25. Becklake MR. Asbestos-related diseases of the lung and other organs; their epidemiology
and implications for clinical practice. Am Rev Respir Dis 1976;114:187.
25a. Bednar ME, Chahinian AP. Paclitaxel and carboplatin for malignant mesothelioma.
Proc Am Soc Clin Oncol 1999;18:496a.
26. Belani CP, Herndon J, Vogelzang NJ, Green MR. Edatrexate for malignant mesothelioma.
A phase II study of the Cancer and Leukemia Group B. Proc Am Soc Clin
Oncol 1994;13:329.
26a. Belani CP, Adak S, Aisner S, et al. Docetaxel for malignant mesothelioma. Phase II
study of the Eastern Cooperative Oncology Group (ECOG 2595). Proc Am Soc
Clin Oncol 1999;18:474a.
26b. Benard F, Sterman D, Smith RJ, et al. Prognostic value of FDG PET imaging in
malignant pleural mesothelioma. J Nucl Med 1999;40:1241.
27. Blake PR, Catterall M, Emerson, PA. Pleural mesothelioma treated by fast neutron
therapy. Thorax 1985;40:72.
28. Bonadonna G, Beretta G, Tancini G, et al. Adriamycin (NSC-123127) studies at the
Istituto Nazionale Tumori, Milan. Cancer Chemother Rep 1975;6(Part 3):231.
29. Bonadonna G, Beretta G, Tancini G, et al. Monochemioterapia con adriamicina in
varie neoplasie in fase avanzata dell' adulto e del bambino. Tumori 1974;60:373.
30. Boutin C, Irisson M, Guerin JC, et al. Phase II trial of vindesine in malignant pleural
mesothelioma. Cancer Treat Rep 1987;71:205.
31. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma. A prospective
study of 188 consecutive patients. Part 1: diagnosis. Cancer 1993;72:389.
32. Boutin C, Rey F, Gouvernet J, et al. Thoracoscopy in pleural malignant mesothelioma.
Part 2: prognosis and staging. Cancer 1993;72:394.
33. Boutin C, Viallat JR, Rey F. Thoracoscopy in diagnosis, prognosis and treatment of
mesothelioma. In Antman K, Aisner J, editors. Asbestos-related malignancy.
Orlando, FA: Grune & Stratton; 1987. p. 301.
34. Boutin C, Viallat JR, Van Zandwijk N, et al. Activity of intrapleural recombinant
gamma-interferon in malignant mesothelioma. Cancer 1991;67:2033.
35. Boutin C, Viallat JR, Aelony Y. Practical thoracoscopy. Berlin, Germany: Springer-
Verlag, 1991.
36. Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant
gamma-interferon in early stage malignant pleural mesothelioma. Cancer
1994;74:2460.
36a. Boutin C, Schlesser M, Frenay C, Astoul P. Malignant pleural mesothelioma. Eur
Respir J 1998;12:972.
37. Bowman RV, Manning LS, Davis M, et al. Susceptibility of cultured human malignant
mesothelioma cells to cytotoxic drugs, cytokines, and immune effector
cells: in vitro assessment. Proc Am Assoc Cancer Res 1989;30:611.
37a. Brancatisano RR, Joseph MG, McCaughan BC. Pleurectomy for mesothelioma.
Med J Aust 1991; 154:455.
38. Breau JL, Boaziz C, Morere JF, et al. Chemotherapy with cisplatin, Adriamycin,
bleomycin and mitomycin C, combined with systemic and intrapleural
hyaluronidase in stage II and III pleural mesothelioma. Eur Respir Rev 1993;
3(Rev 11):223.
39. Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant mesothelioma of the
pleura. Review of 123 patients. Cancer 1982;49:2431.
39a. Bright RK, Shearer MH, Pass HI, Kennedy RC. Immunotherapy of SV40 induced
tumours in mice: a model for vaccine development. Dev Biol Stand 1998;94:341.
40. Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the
management of diffuse malignant mesothelioma of the pleura. Experience with
29 patients. Thorax 1976;31:15.
40a. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for
malignant mesothelioma. A phase II study. J Clin Oncol 1999;17:25.
40b. Calavrezos A, Koschel G, Husselmann H, et al. Malignant mesothelioma of the
pleura. A prospective therapeutic study of 132 patients from 1981-1985. Klin
Wochenschr 1988;66:607.
41. Cameron G, Woodworth CD, Edmondson S, Mossman BT. Mechanisms of
asbestos-induced squamous metaplasia tracheobronchial epithelial cells. Environ
Health Perspect 1989;80:101.
42. Campbell GD, Greenberg SD. Pleural mesothelioma with calcified liver metastases.
Chest 1981;79:229.
43. Cantin R, Al-Jabi M, McCaughey WTE. Desmoplastic diffuse mesothelioma. Am J
Surg Pathol 1982;6:215.
43a. Canto A, Guijarro R, Arnau A, et al. Videothoracoscopy in the diagnosis and treatment
of malignant pleural mesothelioma with associated pleural effusions. Thorac
Cardiovasc Surg 1997;45:16.
44. Cantwell BMJ, Earnshaw M, Harris AL. Phase II study of a novel antifolate, N10-
propargyl-5, 8 dideazafolic acid (CB3717), in malignant mesothelioma. Cancer
Treat Rep 1986;70:1335.
45. Cantwell BMJ, Franks CR, Harris AL. A phase II study of the platinum analogues
JM8 and JM9 in malignant pleural mesothelioma. Cancer Chemother Pharmacol
1986;18:286.
46. Carbone M, Pass HI, Rizzo P, et al. Simian virus 40-like DNA sequences in human
pleural mesothelioma. Oncogene 1994;9:1781.
46a. Carbone M, Rizzo P, Grimley PM, et al. Simian virus-40 large-T antigen binds p53
in human mesotheliomas. Nat Med 1997;3:908.
47. Carmichael J, Cantwell BMJ, Harris AL. A phase II trial of ifosfamide/mesna with
doxorubicin for malignant mesothelioma. Eur J Cancer Clin Oncol 1989;25:911.
48. Case Records of the Massachusetts General Hospital. Case 33111. N Engl J Med
1947;236:407.
49. Case Records of the Massachusetts General Hospital. Case 46 1978. N Engl J Med
1978;299:1179.
50. Chabot JF, Beard D, Langlois AJ, Beard JW. Mesotheliomas of peritoneum, epicardium,
and pericardium induced by strain MC29 avian leukosis virus. Cancer
Res 1970;30:1287.
51. Chahinian AP. Case 38 1978. N Engl J Med 1979;300:263.
52. Chahinian AP. Malignant mesothelioma. In: Holland JF, Frei E III, editors. Cancer
medicine, 2nd ed. Philadelphia, PA: Lea & Febiger; 1982. p. 1744.
53. Chahinian AP. Malignant mesothelioma. In: Greenspan EM, editor. Clinical interpretation
and practice of cancer chemotherapy. New York, NY: Raven; 1982. p. 599.
54. Chahinian AP. Therapeutic modalities in malignant pleural mesothelioma. In: Chretien
J, Hirsch A, editors. Diseases of the pleura. New York, NY: Masson; 1983. p. 224.
55. Chahinian AP, Antman K, Goutsou M, et al. Randomized phase II trial of cisplatin
with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and
Leukemia Group B. J Clin Oncol 1993;11:1559.
56. Chahinian AP, Beranek JT, Suzuki Y, et al. Transplantation of human malignant
mesothelioma into nude mice. Cancer Res 1980;40:181.
57. Chahinian AP, Hirsch A, Bignon J, et al. Les pleuresies asbestosiques non tumorales.
A propos de 6 observations, Rev Fr Mal Respir 1973;1:5.
58. Chahinian AP, Holland JF. Treatment of diffuse malignant mesothelioma: a review.
Mt Sinai J Med 1978;45:54.
59. Chahinian AP, Holland JF, Mandel EM. Chemotherapy for malignant mesothelioma
with Adriamycin and continuous infusion of 5-azacytidine. Cancer Treat Rep
1978;62:1108.
60. Chahinian AP, Kirschner PA, Gordon RE, et al. Usefulness of the nude mouse model
in mesothelioma based on a direct patient xenograft comparison. Cancer 1991;
68:558.
61. Chahinian AP, Norton L, Holland JF, et al. Experimental and clinical activity of mitomycin
C and cis-diamminedichloroplatinum in malignant mesothelioma. Cancer
Res 1984;44:1688.
62. Chahinian AP, Pajak TF, Holland JF, Green G. Adverse prognostic significance of
thrombocytosis in patients with malignant mesothelioma. Proc Am Assoc Cancer
Res 1984;25:161.
63. Chahinian AP, Pajak TF, Holland JF, et al. Diffuse malignant mesothelioma.
Prospective evaluation of 69 patients. Ann Intern Med 1982;96:746.
64. Chahinian AP, Suzuki Y, Mandel EM, Holland JF. Diffuse pulmonary malignant
mesothelioma. Response to doxorubicin and 5-azacytidine. Cancer 1978;42:1687.
64a Chahinian AP, Rusch VW. Malignant mesothelioma. In: Holland JF, Frei III E, Bast
RC, Kufe DW, Morton D, Weichselbaum RR, editors. Cancer medicine, 4th ed.
Baltimore, MD: Williams & Wilkins; 1997. p. 1805-1826.
64b. Charvat JC, Brutsche M, Frey JG, Tschopp JM. Value of thoracoscopy and talc pleurodesis
in diagnosis and palliative treatment of malignant pleural mesothelioma.
Schweiz Rundsch Med Prax 1998; 87:336.
CHAPTER 89 / Malignant Mesothelioma 1307
1308 SECTION 28 / Neoplasms of the Thorax patients with mesothelioma. A National Cancer Institute of Canada Clinical Trials
Group study. Cancer Treat Rep 1986;70:1029.
93. Elmes PC. The natural history of diffuse mesothelioma. In: Bogovoski P, Gilson JC,
Timbrell V, Wagner JC, editors. Biological effects of asbestos. Lyon, France:
International Agency for Research on Cancer; 1973. p. 267.
94. Enterline EP, Henderson VL. Geographic patterns for pleural mesothelioma deaths
in the United States 1986-81. J Clin Oncol 1987;79:31.
95. Epler GR, McLoud TC, Gaensler EA. Prevalence and incidence of benign asbestos
pleural effusion in a working population. JAMA 1982;247:617.
96. Eschwege S, Schlienger M. La radiotherapie des mesotheliomes pleuraux malins. A
propos de 14 cas irradies a doses elevees. J Radiol Electrol (Paris) 1973;54:255.
96a. Faber LP. Extra pleural pneumonectomy for diffuse, malignant mesothelioma. Ann
Thorac Surg 1994; 58:1782.
97. Falkson G, Vorobiof DA, Simson IW, Borden EC. Phase II trial of acivicin in malignant
mesothelioma. Cancer Treat Rep 1987;71:545.
98. Feins RH, Hgilf R, Ross H, Gibson SL. Photodynamic therapy for human malignant
mesothelioma in the nude mouse. J Surg Res 1990;49:311.
99. Fer MF, Beatty PG, Richardson RL, Greco FA. Combination chemotherapy of
malignant mesothelioma with cyclophosphamide, Adriamycin and vincristine.
Cancer Chemother Pharmacol 1980;4:135.
100. Fletcher JA, Kozakewich HP, Hoffer FA, et al. Diagnostic relevance of clonal cytogenetic
aberrations in malignant soft-tissue tumors. N Engl J Med 1991;324:436.
101. Foulke RS, Davision K, Zaloznik AJ, Hoff DV. Absence of oncogene amplification
in malignant mesothelioma specimens. Proc Am Soc Clin Oncol 1991;10:302.
102. Fraire AE, Cooper S, Greenberg SD, et al. Mesothelioma of childhood. Cancer
1988;62:838.
103. Gabrielson EW, Lechner JF, Gerwin BI, et al. Growth factors for mesothelial and
mesothelioma cells. Chest 1987;91:17S.
104. Gardner MJ, Acheson ED, Winter PD. Mortality from mesothelioma of the pleura
during 1968-78 in England and Wales. Br J Cancer 1982;4:81.
105. Garlepp MJ, Christmas TI, Manning LS, et al. The role of platelet-derived growth
factor in the growth of human malignant mesothelioma. Eur Respir Rev
1993;3(Rev 11):189.
106. Gerber M. Asbestos and neoplastic disorders of the hematopoietic system. Am J
Clin Pathol 1970;53:204.
107. Gerner RE, Moore GE. Chemotherapy of malignant mesothelioma. Oncology
1974;30:152.
108. Gerwin BI, Lechner JF, Reddel RR, et al. Comparison of production of transforming
growth factor-_ and platelet-derived growth factor by normal human
mesothelial cells and mesothelioma cell lines. Cancer Res 1987;47:6180.
109. Gibas Z, Li FP, Antman KH, et al. Chromosome changes in malignant mesothelioma.
Cancer Genet Cytogenet 1986;20:191.
110. Gold C. A primary mesothelioma involving the rectovaginal septum and associated
with beryllium. J Pathol Bacteriol 1967;93:435.
111. Goldsmith MS, Ohnuma T, Jaffrey IH, et al. Phase I study of mitoxantrone on a daily
3 5 schedule. Am J Clin Oncol 1984;7:567.
112. Gordon W, Antman KH, Greenberger JS, et al. Radiation therapy in the management
of patients with mesothelioma. Int J Radiat Oncol Biol Phys 1981;8:19.
113. Gotfried MH, Quan SF, Sobonya RE. Diffuse epithelial pleural mesothelioma presenting
as a solitary lung mass. Chest 1983;84:99.
114. Gottlieb JA, Baker LH, Quagliana JM, et al. Chemotherapy of sarcomas with a combination
of Adriamycin and dimethyl triazeno imidazole carboxamide. Cancer
1972;30:1632.
115. Gottlieb JA, Bodey GP, Sinkovics JG, et al. An effective new 4-drug combination
regimen (CY-VA-DIC) for metastatic sarcomas. Proc Am Assoc Cancer Res
1974;15:162.
116. Grundy GW, Miller RW. Malignant mesothelioma in childhood. Report of 3 cases.
Cancer 1972;30:1216.
117. Harington JS. Fiber carcinogenesis: epidemiologic observations and the Stanton
hypothesis. J Natl Cancer Inst 1981;67:977.
118. Harmon D, Vogelzang N, Roboz M, et al. Dihydro-5-azactidine (DHAC) in malignant
mesothelioma (MESO) using serum hyaluronic acid (SHA) as a tumor
marker. A phase II trial of the CALGB. Proc Am Soc Clin Oncol 1991;10:351.
119. Harvey JC, Fleischman EH, Kagan AR, Streeter OE. Malignant pleural mesothelioma:
a survival study. J Surg Oncol 1990;45:40.
120. Harvey VJ, Slevin ML, Ponder BAJ, et al. Chemotherapy of diffuse malignant
mesothelioma. Cancer 1984;54:961.
121. Harwood TR, Gracey DR, Yokoo H. Pseudomesotheliomatous carcinoma of the
lung. A variant of peripheral lung cancer. Am J Clin Pathol 1976;65:161.
122. Henderson DW, Attwood HD, Constance J, et al. Lymphohistiocytoid mesothelioma.
A rare lymphomatoid variant of predominantly sarcomatoid mesothelioma.
Ultrastruct Pathol 1988;12:367.
123. Henss H, Fiebig HH, Schildge J, et al. Phase II study with the combination of cisplatin
and doxorubicin in advanced malignant mesothelioma of the pleura.
Onkologie 1988;11:118.
124. Herbert A. Pathogenesis of pleurisy, pleural fibrosis, and mesothelial proliferation.
Thorax 1986;41:176.
124a Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among
337 patients with mesothelioma treated between 1984 and 1994 by the Cancer
and Leukemia Group B. Chest 1998;113:723.
125. Higashihara M, Sunaga S, Tange T, et al. Increased secretion of interleukin-6 in
65. Cheng JQ, Jhanwar SC, Kein WM, et al. p16 alterations and deletion mapping of
9p21-p22 in malignant mesothelioma. Cancer Res 1994;54:5547.
66. Chretien J, Delobel J, Brouet G. DonneZs etiologiques concernant 15 observations
de mesotheliomes malins de la plevre. Poumon Coeur 1968;24:549.
67. Christmas TI, Musk AW, Robinson BWS. Phase II study of recombinant human
alpha interferon therapy in malignant pleural mesothelioma. Proc Am Assoc
Cancer Res 1990;31:283.
68. Churg A. Chrysotile, tremolite, and malignant mesothelioma in man. Chest
1988;93:621.
69. Churg J, Rosen SH, Moolten S. Histological characteristics of mesothelioma associated
with asbestos. Ann NY Acad Sci 1965;32:614.
70. Colbert N, Vannetzel JM, Izrael V, et al. A prospective study of detorubicin in malignant
mesothelioma. Cancer 1985;56:2170.
71. Connelly RR, Spirtas R, Myers MH, et al. Demographic patterns for mesothelioma
in the United States. J Clin Oncol 1987;78:1053.
71a. Conlon KC, Rusch VW, Gillern S. Laparoscopy: an important tool in the staging of
malignant pleural mesothelioma. Ann Surg Oncol 1996; 3:489.
71b. Costanzi J, Darzynkiewicz Z, Chun H, et al. The use of Onconase for patients with
advanced malignant mesothelioma. Fourth International mesothelioma Conference.
Philadelphia, PA: International Mesothelioma Interest Group; May 13-15,
1997.
72. Cote RJ, Jhanwar S, Novick S. Genetic alterations of the p53 gene are a common
feature of malignant mesotheliomas. Proc Am Assoc Cancer Res 1991;32:301.
73. Cowan JD, Green S, Lucas J, et al. Phase II trial of five day intravenous infusion vinblastine
sulfate in patients with diffuse malignant mesothelioma. A Southwest
Oncology Group study. Invest New Drugs 1988;6:247.
74. Craig JR, Hart WR. Extragenital adenomatoid tumor. Cancer 1979;43:1678.
75. Dabouis G, Le Mevel B, Corroller J. Treatment of diffuse pleural malignant
mesothelioma by cis dichloro diammine platinum (C.D.D.P.) in nine patients.
Cancer Chemother Pharmacol 1981;5:209.
76. Dahl IMS, Laurent TC. Concentration of hyaluronan in the serum of untreated cancer
patients with special reference to patients with mesothelioma. Cancer
1988;62:326.
77. Dahl IMS, Solheim OP, Erikstein B, Muller E. A longitudinal study of the hyaluronan
level in the serum of patients with malignant mesothelioma under treatment.
Cancer 1989;64:68.
78. David R, Hiss Y. Corpora amylacea in mesothelioma of the atrioventricular node. J
Pathol 1978;124:111.
79. Daya D, McCaughey E. Well-differentiated papillary mesothelioma of the peritoneum.
A clinicopathologic study of 22 cases. Cancer 1990;65:292.
80. Dazzi H, Hasleton PS, Thatcher N, et al. Malignant pleural mesothelioma and epidermal
growth factor receptor EGF-R with histology and survival using fixed
paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990;
61:924.
80a. De Luca A, Baldi A, Esposito V, et al. The retinoblastoma gene family pRb/p105,
p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas.
Nat Med 1997;3:913.
81. Dhingra H, Umsawasdi T, Holoye P, et al. Phase II trial of 5,6-dihydroazacytidine in
pleural malignant mesothelioma. Proc Am Assoc Cancer Res 1989;30:274.
82. Dimitrov NV, Egner J, Balcueva E, Suhrland L. High-dose methotrexate with citrovorum
factor and vincristine in the treatment of malignant mesothelioma. Cancer
1982;50:1245.
83. Dimitrov NV, McMahon S. Presentation, diagnostic methods, staging, and natural
history of malignant mesothelioma. In: Antman K, Aisner J, editors. Asbestosrelated
malignancy. Orlando, FA: Grune & Stratton; 1987. p. 225.
84. Djerassi I, Kim JS, Kassarov L, Reggev A. Response of mesothelioma to large doses
of methotrexate with CF rescue (HDMTX-CF) used alone or with cis-platinum.
Proc Am Soc Clin Oncol 1985;4:191.
85. Doll R, Peto J. Other asbestos-related neoplasms. In: Antman K, Aisner J, editors.
Asbestos-related malignancy. Orlando, FA: Grune & Stratton; 1987. p. 81.
86. Donna A, Betta PG, Jones JSP. Verification of the histologic diagnosis of malignant
mesothelioma in relation to the binding of an antimesothelial cell antibody. Cancer
1989;63:1331.
87. Eagan RT, Frytak S, Richardson RL, et al. Phase II trial of diaziquone in malignant
mesothelioma. Cancer Treat Rep 1986;70:429.
88. Earhart RH, Amato DJ, Chang AYC, et al. Phase II trial of 6 diazo-5-oxo-L-norleucine
versus aclacinomycin-A in advanced sarcomas and mesotheliomas.
Invest New Drugs 1990;8:113.
89. Efremidis AP, Waxman JS, Chahinian AP. Association of lymphocytic neoplasia and
mesothelioma. Cancer 1985;55:1056.
90. Eggermont AMM, Goey SH, Slingerland R, et al. Clinical and immunological evaluation
of intrapleural (IPL) interleukin-2 (IL-2) in malignant pleural mesothelioma:
a phase I-II study. Proc Am Assoc Cancer Res 1991;32:206.
90a. Eiselberg AV. Im protokoll der Gesellschaft der Artze in Wien. Wien klin wochenschr
1922;509.
91. Eisenhauer EA, Evans WK, Murray N, et al. A phase II study of VP16 and cisplatin
in patients with unresectable malignant mesothelioma. An NCI of Canada Clinical
Trials Group study. Invest New Drugs 1988;6:327.
92. Eisenhauer EA, Evans WK, Raghavan D, et al. Phase II study of mitoxantrone in
malignant mesothelioma cells from a patient with marked thrombocytosis. Cancer
1992;70:2105.
126. Hilaris BS, Nori D, Kwong E, et al. Pleurectomy and intraoperative brachytherapy
and postoperative radiation in the treatment of malignant pleural mesothelioma.
Int J Radiat Oncol Biol Phys 1984;10:325.
127. Hillerdal G. Malignant mesothelioma 1982: review of 4710 published cases. Br J
Dis Chest 1983;77:321.
127a. Hoffman KR. Paclitaxel and carboplatin combination chemotherapy is an effective
palliative treatment form malignant mesothelioma. Proc Am Soc Clin Oncol
1996;15:455.
128. Hoffman J, Mintzer D, Warhol MJ. Malignant mesothelioma following radiation
therapy. Am J Med 1994;97:379.
128a. Hunt KJ, Longton G, Williams MA, Livingston RB. Treatment of malignant
mesothelioma with methotrexate and vinblastine, with or without platinum
chemotherapy. Chest 1996;109:1239.
129. Jara F, Takita H, Rao UNM. Malignant mesothelioma of pleura. Clinicopathologic
observation. NY State J Med 1977;10:1885.
130. Jaurand MC, Fleury J, Monchaux G, et al. Pleural carcinogenic potency of mineral
fibers (asbestos attapulgite) and their cytotoxicity on cultured cells. J Natl Cancer
Inst 1987;79:797.
131. Jaurand MC, Kheuang L, Magne J, Bignon J. Chromosomal changes induced by
chrysotile fibres or benzo-3, 4-pyrene in rat pleural mesothelial cells. Mutat Res
1986;169:141.
131a. Jensik R, Cagle JE, Milloy F, et al. Pleurectomy in the treatment of pleural effusion
due to metastatic malignancy. J Thorac Cardiovasc Surg 1963; 46:322.
132. Jett JR, Eagan RT. Chemotherapy for malignant mesothelioma: CAMEO. Am J Clin
Oncol 1982;5:429.
133. Kagan E, Jacobson RI, Yeung KY, Haidak DJ. Asbestos-associated neoplasms of B
cell lineage. Am J Med 1979;67:325.
134. Kane JM, Chahinian AP, Holland JF. Malignant mesothelioma in young adults. Cancer
1990;65:1449.
135. Kankel E, Koschel G, Gatzemeyer U, Salewski E. A phase II study of pirarubicin in
malignant pleural mesothelioma. Cancer 1990;66:651.
136. Kannerstein M, Churg J. Peritoneal mesothelioma. Hum Pathol 1977;8:83.
137. Kannerstein M, Churg J, McCaughey WTE, Hill DP. Papillary tumors of the peritoneum
in women: mesothelioma or papillary carcinoma. Am J Obstet Gynecol
1977;127:306.
138. Kannerstein M, Churg J, McCaughey E, Selikoff J. Pathogenic effects of asbestos.
Arch Pathol Lab Med 1977;101:623.
138a. Kasseyet S, Astoul P, Boutin C. Results of a phase II trial of combined chemotherapy
for patients with diffuse malignant mesothelioma of the pleura. Cancer
1999;85:1740.
139. Keller SM, Taylor DD, Weese JL. Photodynamic therapy of human malignant
mesothelioma xenografts in nude mice. Proc Am Assoc Cancer Res 1990;31:392.
140. Kelsen D, Gralla R, Cheng E, Martini N. Vindesine in the treatment of malignant
mesothelioma: a phase II study. Cancer Treat Rep 1983;67:821.
141. Kishimoto T, Ono T, Okada K. Acute myelocytic leukemia after exposure to
asbestos. Cancer 1988;62:787.
142. Kittle CF. Treatment I. The surgical treatment of mesothelioma. In: Kittle CF, editor.
Mesothelioma: diagnosis and management. Chicago, IL: Year Book; 1987. p 31.
143. Klemperer P, Rabin CB. Primary neoplasms of the pleura. A report of five cases.
Arch Pathol 1931;11:385.
144. Klima M, Gyorkey F. Benign pleural lesions and malignant mesothelioma. Virchows
Arch A Path Anat Histol 1977;376:181.
145. Klominek J, Karl-Henrik R, Hjerpe A, et al. Serum-dependent growth patterns of two
newly established human mesothelioma cell lines. Cancer Res 1989;49:6118.
145a. Knuuttila A, Halme M, Kivisaari L, et al. The clinical importance of magnetic resonance
imaging versus computed tomography in malignant pleural mesothelioma.
Lung Cancer 1998;22:215.
146. Kucuksu N, Thomas W, Ezdinli EZ. Chemotherapy of malignant diffuse mesothelioma.
Cancer 1976;37:1265.
147. Kutcher GJ, Kestler RT, Greenblatt D, et al. Technique for external beam treatment
for mesothelioma. Int J Radiat Oncol Biol Phys 1987;13:1747.
148. Kwee WS, Veldhuizen RW, Alons CA, et al. Quantitative and qualitative differences
between benign and malignant mesothelial cells in pleural fluid. Acta Cytol
1982;26:401.
149. Lamb P, Wiseman R, Ozawa N, et al. Detection of transforming genes in human
mesotheliomas. Proc Am Assoc Cancer Res 1988;29:142.
150. Langer AM, Noland RP, Constantopoulos SH, Moutsopoulos HM. Association of
metsovo lung and pleural mesothelioma with exposure to tremolite-containing
whitewash. Lancet 1987;1:965.
151. Langer AM, Selikoff IJ, Sastre A. Chrysotile asbestos in the lungs of persons in New
York City. Arch Environ Health 1971;22:348.
152. Law MR, Gregor A, Hodson M, et al. Malignant mesothelioma of the pleura: a study
of 52 treated and 64 untreated patients. Thorax 1984;39:255.
153. Lechner JF, Tokiwa T, LaVeck M, et al. Asbestos-associated chromosomal changes
in human mesothelial cells. Proc Natl Acad Sci USA 1985;82:3884.
154. Lee TC, Zhang Y, Aston C, et al. Normal human mesothelial cells and mesothelioma
cell lines express insulin-like growth factor I and associated molecules. Cancer
Res 1993;53:2858.
155. Legha SS, Muggia FM. Therapeutic approaches in malignant mesothelioma. Cancer
Treat Rev 1977;4:13.
156. Lerner HJ, Schoenfeld DA, Martin A, et al. Malignant mesothelioma. The Eastern
Cooperative Group (ECOG) experience. Cancer 1983;52:1981.
157. Lew F, Tsang P, Holland JF, et al. High frequency of immune dysfunctions in
asbestos workers and in patients with malignant mesothelioma. J Clin Immunol
1986;6:225.
158. Lewis RJ, Sisler GE, Mackenzie JW. Diffuse, mixed malignant pleural mesothelioma.
Ann Thorac Surg 1981;31:53.
159. Libbus BL, Illenye SA, Craighead JE. Induction of DNA strand breaks in cultured
rat embryo cells by crocidolite asbestos as assessed by Nick translation. Cancer
Res 1989;49:5713.
160. Lofgren L, Larsson M, Thaning L, Hallgren S. Transthoracic endoscopic photodynamic
treatment of malignant mesothelioma. Lancet 1991;337:359.
161. Maasilta P. Deterioration in lung function following hemithorax irradiation for pleural
mesothelioma. Int J Radiat Oncol Biol Phys 1991;20:433.
162. Magri MD, Foladore S, Veronesi A, et al. Treatment of malignant mesothelioma with
epirubicin and ifosfamide. A phase II cooperative study. Ann Oncol 1992;3:237.
163. Magri MD, Veronesi A, Foladore S, et al. Epirubicin in the treatment of malignant
mesothelioma. A phase II cooperative study. The North-Eastern Italian Oncology
Group (GOCCNE) Mesothelioma Committee Tumori 1991;77:49.
163a. Maksymiuk AW, Marschke RF Jr, Tazelaar HD, et al. Phase II trial of topotecan for
the treatment of mesothelioma. Am J Clin Oncol 1998;21:610-613.
164. Manning LS, Bowman RV, Darby SB, Robinson BWS. Lysis of human malignant
mesothelioma cells by natural killer (NK) and lymphokine-activated killer
(LAK) cells. Am Rev Respir Dis 1989;139:1369.
165. Markman M, Cleary S, Pfeifle C, Howell SB. Cisplatin administered by the intracavitary
route as treatment for malignant mesothelioma. Cancer 1986;58:18.
166. Markman M, Kelsen D. Intraperitoneal cisplatin and mitomycin as treatment for
malignant peritoneal mesothelioma. Reg Cancer Treat 1989;2:49.
167. Maroudas NG, O'Neill CH, Stanton MF. Fibroblast anchorage in carcinogenesis by
fibers. Lancet 1973;1:807.
168. Marsh JP, Mossman BT. Mechanisms of induction of ornithine decarboxylase activity
in tracheal epithelial cells by asbestiform minerals. Cancer Res 1988;48:709.
169. Marsh JP, Mossman BT. Role of asbestos and active oxygen species in activation and
expression of ornithine decarboxylase in hamster tracheal epithelial cells. Cancer
Res 1991;51:167.
170. Martensson G, Hagmar B, Zettergren L. Diagnosis and prognosis in malignant pleural
mesothelioma: a prospective study. Eur J Respir Dis 1984;65:169.
171. Martensson G, Larsson S, Zettergren L. Malignant mesothelioma in two pairs of siblings:
is there a hereditary predisposing factor? Eur J Respir Dis 1984;65:179.
172. Martensson G, Sorenson S. A phase II study of vincristine in malignant mesothelioma;
a negative report. Cancer Chemother Pharmacol 1989;24:133.
173. Mattson K, Giaccone G, Kirkpatrick A, et al. Epirubicin in malignant mesothelioma.
A phase II study of the European Organization for Research and Treatment
of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1992;10:824.
174. Mbidde EK, Harland SJ, Calvert AH, et al. Phase II trial of carboplatin (JM8) in
treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol
1986;18:284.
175. McAuley P, Asa SL, Chiu B, et al. Parathyroid hormone-like peptide in normal and
neoplastic mesothelial cells. Cancer 1990;66:1975.
176. McCormack PM, Nagasaki F, Hilaris BS, Martini N. Surgical treatment of pleural
mesothelioma. J Thorac Cardiovasc Surg 1982;84:834.
177. McDonald JC, Armstrong B, Case B, et al. Mesothelioma and asbestos fiber type.
Evidence from lung tissue analysis. Cancer 1989;63:1544.
178. McGowan L, Bunnag B, Arias LF. Mesothelioma of the abdomen in women: monitoring
of therapy by peritoneal fluid study. Gynecol Oncol 1975;3:10.
179. Menzies R, Charbonneau M. Thoracoscopy for the diagnosis of pleural disease. Ann
Intern Med 1991;114:271.
180. Metcalf RA, Welsh JA, Bennett WP, et al. p53 and Kirsten-ras mutations in human
mesothelioma cell lines. Cancer Res 1992;52:2610.
180a. Metintas M, Ozdemir N, Ucgun I, et al. Cisplatin, mitomycin, and interferon-a2a
combination chemoimmunotherapy in the treatment of diffuse malignant pleural
mesothelioma. Chest 1999;116:391.
180b. Middleton GW, Smith IE, O'Brien ME, et al. Good symptom relief with palliative
MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant
mesothelioma. Ann Oncol 1998;9:269.
181. Mintzer DM, Kelsen K, Frimmer D, et al. Phase II trial of high-dose cisplatin in
patients with malignant mesothelioma. Cancer Treat Rep 1985;69:711.
182. Moertel CG. Peritoneal mesothelioma. Gastroenterology 1972;63:346.
183. Mossman BT, Bignon J, Corn M, et al. Asbestos: scientific developments and implications
for public policy. Science 1990;247:294.
184. Mossman BT, Craighead JE, MacPherson BV. Asbestos-induced epithelial changes
in organ cultures of hamster trachea: inhibition by retinyl methyl ether. Science
1980;207:311.
185. Mossman BT, Gee JBL. Asbestos-related diseases. N Engl J Med 1989;320:1721.
186. Mychalezak BR, Nori D, Armstrong JG, et al. Results of treatment of malignant
pleural mesothelioma with surgery, brachytherapy, and external beam irradiation.
Proc Am Endocurietherapy Soc 1989;12.
187. Nakano T, Fujii J, Tamura S, et al. Thrombocytosis in patients with malignant pleural
mesothelioma. Cancer 1986;58:1699.
CHAPTER 89 / Malignant Mesothelioma 1309
1310 SECTION 28 / Neoplasms of the Thorax 209. Rich S, Presant CA, Meyer J, et al. Human chorionic gonadotropin and malignant
mesothelioma. Cancer 1979;43:1457.
210. Rice TW, Adelstein DJ, Kirby TJ, et al. Aggresssive multimodality therapy for
malignant pleural mesothelioma. Ann Thorac Surg 1994;58:24.
211. Riddell RH, Goodman MJ, Moossa AR. Peritoneal malignant mesothelioma in a
patient with recurrent peritonitis. Cancer 1981;48:134.
212. Risberg B, Nickels J, Wagermark J. Familial clustering of malignant mesothelioma.
Cancer 1980;45:2422.
213. Rivkin SE, Gottlieb JA, Thigpen T, et al. Methyl CCNU and Adriamycin for patients
with metastatic sarcomas. A Southwest Oncology Group study. Cancer 1980;
46:446.
214. Roberts GH. Diffuse pleural mesothelioma: a clinical pathological study. Br J Dis
Chest 1970;64:201.
215. Robinson BWS. Asbestos and cancer: human natural killer cell activity is suppressed
by asbestos fibers but can be restored by recombinant interleukin-2. Am
Rev Respir Dis 1989;139:897.
216. Roboz J, Chahinian AP, Holland JF, et al. Early diagnosis and monitoring of transplanted
human malignant mesothelioma by serum hyaluronic acid. J Natl Cancer
Inst 1989;81:924.
217. Roboz J, Greaves J, Silides D, et al. Hyaluronic acid content of effusions as a diagnostic
aid for malignant mesothelioma. Cancer Res 1985;45:1850.
218. Rogers AJ, Leigh J, Berry G, et al. Relationship between lung asbestos fiber type
and concentration and relative risk of mesothelioma. A case-control study. Cancer
1991;67:1912.
219. Roggli VL, McGavran MH, Subach J, et al. Pulmonary asbestos body counts and
electron probe analysis of asbestos body cores in patients with mesothelioma. A
study of 25 cases. Cancer 1982;50:2423.
220. Rogoff EE, Hilaris BS, Huvos AG. Long term survival in patients with malignant
peritoneal mesothelioma treated with irradiation. Cancer 1973;32:656.
221. Rom WN, Travis WD, Brody AR. Cellular and molecular basis of the asbestosrelated
diseases. Am Rev Respir Dis 1991;143:408.
222. Ross R, Nichols P, Wright W, et al. Asbestos exposure and lymphomas of the gastrointestinal
tract and oral cavity. Lancet 1982;2:1118.
223. Ross MJ, Welch WR, Scully RE. Multilocular peritoneal inclusion cysts (so-called
cystic mesotheliomas). Cancer 1989;64:1336.
224. Roviaro GC, Sartori F, Calabro F, Varoli F. The association of pleural mesothelioma
and tuberculosis. Am Rev Respir Dis 1982;126:569.
225. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in
Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol
1989;7:1157.
226. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in
malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac
Cardiovasc Surg 1991;102:1.
227. Rusch VW, Dillard D. Pleural mesothelioma. In Pearson FG, Deslauriers J, Ginsberg
RJ, et al., editors. Thoracic surgery. New York, NY: Churchill Livingstone; 1994.
p. 1083.
228. Rusch VW, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy/decortication
followed by intrapleural and systemic chemotherapy for malignant pleural
mesothelioma. J Clin Oncol 1994;12:1156.
229. Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of
malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996; 111:815.
229a. Rusch VW. A proposed new international TNM staging system for malignant pleural
mesothelioma. Chest 1995; 108:1122.
230. Ryan CJ, Rodgers RF, Unni KK, Hepper NGG. The outcome of patients with pleural
effusion of indeterminate cause at thoracotomy. Mayo Clin Proc 1981;56:145.
230a. Sahmoud T, Postmus PE, Van Pottelsberghe C, et al. Etoposide in malignant pleural
mesothelioma. Two phase II trials of the EORTC Lung Cancer Cooperative
Group. Eur J Cancer 1997;33:2211.
230b. Samuels BL, Herndon JE, Harmon DC, et al. Dihydro-5-azacytidine and cisplatin
in the treatment of malignant mesothelioma. A phase II study by the Cancer and
Leukemia Group B. Cancer 1998; 82:1578.
231. Samson MK, Baker LH, Benjamin RS, et al. Cis-dichlorodiammineplatinum (II) in
advanced soft tissue and bony sarcomas. A Southwest Oncology Group study.
Cancer Treat Rep 1979;63:2027.
232. Samson MK, Wasser LP, Borden EC, et al. Randomized comparison of cyclophosphamide,
imidazole carboxamide, and Adriaymcin versus cyclophosphamide
and Adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma
Intergroup study. J Clin Oncol 1987;1:86.
233. Samuels BL, Herndon JE, Harmon DC, et al. Dihydro-5-azacytidine and cisplatin
in the treatment of malignant mesothelioma. Cancer 1998;82:1578.
234. Schneider V, Patridge JR, Gutierrez F, et al. Benign cystic mesothelioma involving
the female genital tract: report of four cases. Am J Obstet Gynecol 1983;145:355.
235. Schoenfeld DA, Rosenbaum C, Horton J, et al. A comparison of Adriamycin versus
vincristine and Adriamycin, and cyclophosphamide versus vincristine, actinomycin-
D and cyclophosphamide for advanced sarcoma. Cancer 1982;50:2757.
235a. Schwarzenberger P, Harrison L, Weinacker A, et al. The treatment of malignant
mesothelioma with a gene modified cancer cell line: a phase I study. Hum Gene
Ther 1998; 9:2641.
236. Selikoff IJ, Churg J, Hammond EC. Relation between exposure to asbestos and
mesothelioma. N Engl J Med 1965;272:560.
237. Selikoff IJ, Hammond EC. Asbestos and smoking [editorial]. JAMA 1979;242:458.
238. Selikoff IJ, Lee DHK. Asbestos and disease. New York, NY: Academic; 1978.
188. Nakano T, Miyake M, Takenaka N, et al. A pilot phase II study of cisplatin, doxorubicin,
and vindesine for the treatment of malignant pleural mesothelioma. Eur
Resp Rev 1993;3(Rev 11):211.
188a. Nakano T, Chahinian AP, Shinjo M, et al. Cisplatin in combination with irinotecan
in the treatment of patients with malignant pleural mesothelioma. A pilot phase
II clinical trial and pharmacokinetic profile. Cancer 1999; 85:2375.
188b Nakano T, Chahinian AP, Shinjo M, et al. Interleukin 6 and its relationship to clinical
parameters in patients with malignant pleural mesothelioma. Br J Cancer
1998;77:907.
189. Nauta RJ, Osteen RT, Antman KH, Koster JK. Clinical staging and the tendency of
malignant pleural mesotheliomas to remain localized. Ann Thorac Surg
1982;34:66.
190. Nicholson WJ, Perkel G, Selikoff IJ. Occupational exposure to asbestos: population
at risk and projected mortality-1980-2030. Am J Indust Med 1982;3:259.
190a. Ogretmen B, Bahadori H, McCauley M, et al. Co-ordinated over-expression of the
MRP and gamma-glutamylcysteine synthetase genes, but not MDR1, correlates
with doxorubicin resistance in human malignant mesothelioma cell lines. Int J
Cancer 1998; 75:757.
191. O'Hara CJ, Corson JM, Pinkus GS, Stahel RA. A monoclonal antibody that distinguishes
epithelial-type malignant mesothelioma from pulmonary adenocarcinoma
and extrapulmonary malignancies. Am J Pathol 1990;136:421.
192. Parkes WR. Asbestos-related disorders. Br J Dis Chest 1973;67:261.
193. Parmley TH, Woodruff JD. The ovarian mesothelioma. Am J Obstet Gynecol
1974;120:234.
194. Pass HI, Tochner Z, Delaney T, et al. Intraoperative photodynamic therapy for malignant
mesothelioma. Ann Thorac Surg 1990;50:687.
195. Pass HI. Contemporary approaches in the investigation and treatment of malignant
pleural mesothelioma. Chest Surg Clin North Am 1994;4:497.
195a. Pass H, Rizzo P, Donington J, et al. Further validation of SV40-like DNA in human
pleural mesotheliomas. Dev Biol Stand 1998;94:143.
195b. Pass HI, Temeck BK, Kranda K, et al. Preoperative tumor volume is associated with
outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998;
115:310.
195c. Pass HI, Kranda K, Temeck BK, et al. Surgically debulked malignant pleural
mesothelioma: results and prognostic factors. Ann Surg Oncol 1997;4:215.
195d. Pass HI, Donington JS. Use of photodynamic therapy for the management of pleural
malignancies. Semin Surg Oncol 1995; 11:360.
195e. Pennucci MC, Ardizzoni A, Pronzato P, et al. Combined cisplatin, doxorubicin, and
mitomycin for the treatment of advanced pleural mesothelioma. A phase II FONICAP
trial. Cancer 1997;79:1897.
195f. Perez-Soler R, Walsh GL, Shwisher SG, et al. Phase II study of liposome-entrapped
cisplatin analog NDDP administered intrapleurally in patients with malignant
pleural mesothelioma. Proc Am Soc Clin Oncol 1999;18:421a.
196. Persaud V, Bateson EM, Bankay CD. Pleural mesothelioma associated with massive
hepatic calcification and unusual metastases. Cancer 1970;26:920.
197. Peterson JT, Greenberg DS, Buffler PA. Non-asbestos-related malignant mesothelioma.
A review. Cancer 1984;54:951.
198. Pfeifle CE, Howell SB, Markman M. Intracavitary cisplatin chemotherapy for
mesothelioma. Cancer Treat Rep 1985;69:205.
199. Planting A, Schellens JH, Goey HS, et al. Weekly high-dose cisplatin in malignant
pleural mesothelioma. Ann Oncol 1994;5:373.
200. Popescu NC, Chahinian AP, DiPaolo JA. Nonrandom chromosome alterations in
human malignant mesothelioma. Cancer Res 1988;48:142.
201. Presant CA, Lowenbraun S, Bartolucci AA, Smalley RV, the Southeastern Cancer
Study Group. Metastatic sarcomas. Chemotherapy with Adriamycin, cyclophosphamide,
and methotrexate alternating with actinomycin D, DTIC, and vincristine.
Cancer 1981;47:457.
201a. Purohit A, Moreau L, Dietemann A, et al. Weekly systemic combination of cisplatin
and interferon a2a in diffuse malignant pleural mesothelioma. Lung Cancer
1998;22:119.
202. Rabinowitz JG, Efremidis SC, Cohen B, et al. A comparative study of mesothelioma
and asbestosis using computed tomography and conventional chest radiography.
Radiology 1982;144:453.
203. Raghavan D, Gianoutsos P, Bishop J, et al. Phase II trial of carboplatin in the management
of malignant mesothelioma. J Clin Oncol 1990;8:151.
204. Ransom DT, Patel SR, Keeney GL, et al. Papillary serous carcinoma of the peritoneum.
A review of 33 cases treated with platin-based chemotherapy. Cancer
1990;66:1091.
205. Raso V, McGrath J. Cure of experimental human malignant mesothelioma in
athymic mice by diphtheria toxin. J Natl Cancer Inst 1989;81:622.
205a. Ratto GB, Civalleri D, Esposito M, et al. Pleural space perfusion with cisplatin in
the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic
study. J Thorac Cardiovasc Surg 1999; 117:759.
206. Ratzer ER, Pool JL, Melamed MR. Pleural mesotheliomas. Clinical experiences
with thirty-seven patients. AJR Am J Roentgenol 1967;99;863.
207. Rebattu P, Merrouche Y, Blay JY, et al. Phase II study of very high dose cisplatin in
the treatment of malignant mesothelioma. Eur Respir Rev 1993;3:11,226.
208. Reddel RR, Malan-Shibley L, Gerwin BI, et al. Tumorigenicity of human mesothelial
cell line transfected with EJ-ras oncogene. J Natl Cancer Inst 1989;81:945.
239. Semb G. Diffuse malignant pleural mesothelioma. A clinicopathological study of 10
fatal cases. Acta Chir Scand 1963;126:78.
240. Sheldon CD, Herbert A, Gallagher PJ. Reactive mesothelial proliferation: a
necropsy study. Thorax 1981;36:901.
240a. Shin DM, Fossella FV, Umsawasdi T, et al. Prospective study of combination
chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable
or metastatic malignant pleural mesothelioma. Cancer 1995;76:2230.
241. Sinoff C, Falkson G, Sandison AG, De Muelenaere G. Combined doxorubicin and
radiation therapy in malignant pleural mesothelioma. Cancer Treat Rep 1982;66:
1605.
242. Sklarin NT, Chahinian AP, Feuer EJ, et al. Augmentation of activity of cisdiamminedichloroplatinum
(II) and mitomycin C by interferon in human malignant
mesothelioma xenografts in nude mice. Cancer Res 1988;48:64.
243. Smit EF, Berendson HH, Postmus PE. Etoposide and mesothelioma. J Clin Oncol
1990;8:1281.
244. Smythe WR, Hwang HC, Amin KM, et al. Use of recombinant adenovirus to transfer
the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms.
An effective in vitro drug sensitization system. Cancer Res 1994;54:2055.
244a. Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High-dose methotrexate in the
treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer
1992;65:956.
245. Sorensen PG, Bach F, Bork E, Hansen HH. Randomized trial of doxorubicin versus
cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep
1985;69:1431.
246. Spremulli E, Wampler G, Regelson W, et al. Chemotherapy of malignant mesothelioma.
Cancer 1977;40:2038.
247. Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma:
the SEER experience. Int J Cancer 1988;41:525.
248. Sridhar KS, Hussein AM, Feun LG, Zubrod G. Activity of pirarubicin (49-0-tetrahydropyranyladriamycin)
in malignant mesothelioma. Cancer 1989;63:1084.
249. Sridhar KS, Ohnuma T, Chahinian AP, Holland JF. Phase I study of acivicin in
patients with advanced cancer. Cancer Treat Rep 1983;67:701.
250. Stahel RA, O'Hara CJ, Waibel R, Martin A. Monocolonal antibodies against
mesothelial membrane antigen discriminate between maligant mesothelioma
and lung adenocarcinoma. Int J Cancer 1988;41:218.
251. Stanton MF, Layard M, Tegeris A, et al. Relation of particle dimension to carcinogenicity
in amphibole asbestoses and other fibrous minerals. J Natl Cancer Inst
1981;67:965.
251a. Steele JPC, Evans MT, Tischkowitz MD, et al. Vinorelbine is an active and well-tolerated
drug for the treatment of malignant mesothelioma. A phase II study. Proc
Am Soc Clin Oncol 1999;18:490a.
252. Steinberg I. Angiocardiography in mesothelioma of the pericardium. Am J
Roentgenol Radiat Ther Nucl Med 1972;114:817.
252a Sterman DH, Kaiser LR, Albelda SM. Advances in the treatment of malignant pleural
mesothelioma. Chest 1999;116:504.
253. Stewart DJ, Gertler SZ, Tomiak A, et al. High dose doxorubicin plus cisplatin in the
treatment of unresectable mesotheliomas. Report of four cases. Lung Cancer
1994;11:251.
254. Stout AP, Murray MR. Localized pleural mesothelioma. Investigation of its characteristics
and histogenesis by the method of tissue culture. Arch Pathol
1942;34:951.
254a. Strickler HD, Rosenberg PS, Devesa SS, et al. Contamination of poliovirus vaccines
with simian virus 40 (1955-1963) and subsequent cancer rates. JAMA 1998;
279:292.
255. Sugarbaker DJ, Heher EC, Lee TH, et al. Extrapleural pneumonectomy, chemotherapy,
and radiotherapy in the treatment of diffuse malignant pleural mesothelioma.
J Thorac Cardiovasc Surg 1991;102:10.
256. Sugarbaker DJ, Mentzer SJ, Strauss G. Extrapleural pneumonectomy in the treatment
of malignant pleural mesothelioma. Ann Thorac Surg 1992;54:941.
257. Sugarbaker DJ, Strauss GM, Lynch TL, et al. Node status has prognostic significance
in the multimodality therapy of diffuse, malignant mesothelioma. J Clin
Oncol 1993;11:1172.
257a. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extra pleural
nodal status, and cell type determine postoperative long-term survival in trimodality
therapy of malignant pleural mesothelioma: results in 183 patients. J
Thorac Cardiovasc Surg 1999; 117:54.
258. Suzuki Y. Pathology of human malignant mesothelioma. Semin Oncol 1980;3:268.
259. Suzuki Y, Chahinian AP, Ohnuma T. Comparative studies of human malignant
mesothelioma in vivo, in xenografts in nude mice, and in vitro. Cancer 1987;
60:334.
260. Suzuki Y, Kannerstein M, Churg J. Electron microscopy of normal, hyperplastic and
neoplastic mesothelium. In: Bogovoski P, Gilson JC, Timbrell V, Wagner JC, editors.
Biological effects of asbestos. Lyon, France: International Agency for
Research on Cancer; 1973. p. 74.
261. Suzuki Y, Kohyama N. Malignant mesothelioma induced by asbestos and zeolite in
the mouse peritoneal cavity. Environ Res 1984;35:277.
262. Tammilehto L. Malignant mesothelioma: prognostic factors in a prospective study
of 98 patients. Lung Cancer 1992;8:175.
263. Takita H, Mang TS, Loewen GM, et al. Operation and intracavitary photodynamic
therapy for malignant pleural mesothelioma. A phase II study. Ann Thorac Surg
1994;58:995.
264. Taryle DA, Lakshminarayan S, Sahn SA. Pleural mesotheliomas; an analysis of 18
cases and review of the literature. Medicine 1976;55:153.
265. Teirstein AS, Chahinian AP, Goldsmith SJ, Sorek M. Gallium scanning in differentiating
malignant from benign asbestos-related pleural disease. Am J Indust Med
1986;9:497.
265a. Testa JR, Carbone M, Hirvonen A, et al. A multi-institutional study confirms the
presence and expression of simian virus 40 in human malignant mesotheliomas.
Cancer Res 1998;58:4505.
266. Thatcher N, Taylor P, Carroll KB, et al. Interleukin-2 in malignant pleural mesothelioma
(and adenocarcinoma of the lung). The use of intrapleural and continuous
intravenous infusions: preliminary results. Cancer Treat Rev 1989;16:161.
266a. Thodtmann R, Depenbrock H, Blatter J, et al. Preliminary results of a phase I study
with MTA (LY231514) in combination with cisplatin in patients with solid
tumors. Semin Oncol 1999; 26(Suppl 6):89.
267. Thomas J, Phythyon JM. Primary mesothelioma of the pericardium. Circulation
1957;15:385.
268. Tiainen M, Tammilehto L, Rautonen J, et al. Chromosomal abnormalities and their
correlations with asbestos exposure and survival in patients with mesothelioma.
Br J Cancer 1989;60:618.
269. Trandafir L, Borel C, Ruffie P, et al. Combined systemic CDDP-interferon alpha in
advanced pleural malignant mesothelioma. Proc Am Soc Clin Oncol 1994;13:
405.
270. Tsavaris N, Mylonakis N, Karvounis N, et al. Combination chemotherapy with cisplatin-
vinblastine in malignant mesothelioma. Lung Cancer 1994;11:299.
271. Tuttle SE, Lucas JG, Bucci DM, et al. Distinguishing malignant mesothelioma from
pulmonary adenocarcinoma: an immunohistochemical approach using a panel of
monoclonal antibodies. J Surg Oncol 1990;45:72.
272. Umsawasdi T, Dhingra HM, Charnsangavej C, Luna MA. A case report of malignant
pleural mesothelioma with long-term disease control after chemotherapy. Cancer
1991;67:48.
273. Vallabhajosula S, Goldsmith SJ, Lipszyc H, et al. 67Ga-transferrin and 67Ga-lactoferrin
binding to tumor cells. Specific versus nonspecific glycoprotein-cell
interaction. Eur J Nucl Med 1983;8:354.
274. Van Breukelen FJ, Mattson K, Giaccone G, et al. Mitoxantrone in malignant
mesothelioma. A study by the EORTC Lung Cancer Cooperative Group. Eur J
Cancer 1991;27:1627.
275. Van De Water JM, Allen WA. Pericardial mesothelioma. Ann Thoracic Surg
1967;3:162.
276. Van Meerbeeck JP, Debruyne C, Van Zandwijk N, et al. Paclitaxel for malignant
pleural mesothelioma. A phase II study of the EORTC Lung Cancer Cooperative
Group. Br J Cancer 1996;74:961.
276a. Van Meerbeeck JP, Baas P, Debruyne C, et al. A phase II study of gemcitabine in
patients with malignant pleural mesothelioma. Cancer 1999;85:2577.
277. Van Niekerk CC, Jap PHK, Thomas CMG, et al. Marker profile of mesothelial cells
versus ovarian carcinoma cells. Int J Cancer 1989;43:1065.
278. Versnel MA, Hagemeijer A, Bouts MJ, et al. Expression of c-sis (PDGF B-chain)
and PDGF a-chain genes in ten human malignant mesothelioma cell lines
derived from primary and metastatic tumors. Oncogene 1988;2:601.
279. Versnel MA, Langerak AW, Van der Kwast TH, et al. Expression of PDGF chains
and PDGF receptors in human malignant and normal mesothelial cell lines. Eur
Respir Rev 1993;3(Rev 11):186.
279a. Viallat JR, Boutin C. Malignant pleural effusions: recourse to early use of talc.
Rev Med Interne 1998;19:811.
280. Vianna NJ, Maslowsky J, Roberts S, et al. Malignant mesothelioma. Epidemiological
patterns in New York State. NY State J Med 1981;81:735.
281. Vianna NJ, Polan AK. Non-occupational exposure to asbestos and malignant
mesothelioma in females. Lancet 1978;1:1061.
282. Vogelzang NJ, Goutsou M, Corson JM, et al. Carboplatin in malignant mesothelioma:
a phase II study of the Cancer and Leukemia Group B. Cancer Chemother
Pharmacol 1990;27:239.
283. Vogelzang NJ, Schultz SM, Iannucci AN, Kennedy BJ. Malignant mesothelioma.
The University of Minnesota experience. Cancer 1984;53:377.
284. Vogelzang NJ, Weissman LB, Herndon JE, et al. Trimetrexate in malignant mesothelioma.
A Cancer and Leukemia Group B phase II study. J Clin Oncol
1994;12:1436.
285. Vogelzang NJ, Herndon JE, Miller A, et al. High-dose paclitaxel plus G-CSF for
malignant mesothelioma. CALGB phase II study 9234. Ann Oncol 1999;10:597.
285a. Vogelzang NJ, Herndon JE II, Cirrincione C, et al. Dihydro-5-azacytidine in malignant
mesothelioma. A phase II trial demonstrating activity accompanied by cardiac
toxicity. Cancer 1997;79:237.
286. Vogler WR, Arkun S, Velez-Garcia E. Phase I study of twice weekly 5-azacytidine
(NSC-102816). Cancer Chemother Rep 1974;58:895.
287. Von Hoff DD, Metch B, Lucas JG, et al. Phase II evaluation of recombinant interferon-
beta (IFN-Beta Ser) in patients with diffuse mesothelioma. A Southwest
Oncology Group study. J Interferon Res 1990;10:531.
288. Voss AC, Wollgens P, Untucht HJ. Das Pleuramesotheliom aus strahlentherapeutischer
Sicht. Strahlentherapie 1974;148:329.
289. Wadler S, Chahinian AP, Slater W, et al. Cardiac abnormalities in patients with diffuse
malignant pleural mesothelioma. Cancer 1986;58:2744.
CHAPTER 89 / Malignant Mesothelioma 1311
1312 SECTION 28 / Neoplasms of the Thorax
305. Whitwell F, Rawcliffe RM. Diffuse malignant pleural mesothelioma and asbestos
exposure. Thorax 1971;26:6.
306. Whitwell F, Scott J, Grimshaw M. Relationship between occupations and asbestosfibre
content of the lungs in patients with pleural mesothelioma, lung cancer, and
other diseases. Thorax 1977;32:377.
307. Worn H. Moglichkeiten und Ergebnisse der chirurgischen Behandlung des malignen
Pleuramesothelioms. Thoraxchirurgie 1974;22:391.
308. Wright GL Jr, Wirth P, Chahinian AP, et al. Monoclonal antibody EVHS-17.392 differentiates
malignant mesothelioma from adenocarcinomas. Proc Am Assoc
Cancer Res 1989;30:351.
309. Wronski M, Burt M. Cerebral metastases in pleural mesothelioma. Case report and
review of the literature. J Neurooncol 1993;17:21.
309a. Xie YC, Hwang C, Overwijk W, et al. Induction of tumor antigen-specific immunity
in vivo by a novel vaccinia vector encoding safety modified simian virus 40 T
antigen. J Natl Cancer Inst 1999; 91:169.
310. Yap BS, Benjamin RS, Burgess MA, Bodey GP. The value of Adriamycin in the
treatment of diffuse malignant mesothelioma. Cancer 1978;42:1692.
311. Yap BS, Benjamin RS, Burgess MA, et al. A phase II evaluation of methyl CCNU
and actinomycin D in the treatment of advanced sarcomas in adults. Cancer
1981;47:2807.
312. Yeh HC, Chahinian AP. Ultrasonography and computed tomography of peritoneal
mesothelioma. Radiology 1980;135:705.
313. Zidar BL, Benjamin RS, Frank J, et al. Combination chemotherapy for advanced
sarcomas of bone and mesothelioma utilizing rubidazone and DTIC. A Southwest
Oncology Group study. Am J Clin Oncol 1983;6:71.
314. Zidar BL, Green S, Pierce HI, et al. Phase II evaluation of cisplatin in unresectable
diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest
New Drugs 1988;6:223.
315. Zidar BL, Metch B, Balcerzak SP, et al. A phase II evaluation of ifosfamide and
mesna in unresectable diffuse malignant mesothelioma: a Southwest Oncology
Group study. Cancer 1992;70:2547.
316. Zidar BL, Pugh RP, Schiffer LM, et al. Treatment of six cases of mesothelioma with
doxorubicin and cisplatin. Cancer 1983;52:1788.
290. Wagner JC, Berry G, Skidmore JW, Timbrell V. The effects of the inhalation of
asbestos in rats. Br J Cancer 1974;29:252.
291. Wagner JC, Gilson JC, Berry G, Timbrell V. Epidemiology of asbestos cancer. Br
Med Bull 1971;27:71.
292. Wagner JC, Hill RJ, Berry G, Wagner MMF. Treatments affecting the rate of
asbestos-induced mesotheliomas. Br J Cancer 1980;41:918.
293. Wagner JC, Newhouse ML, Corrin B, et al. Correlation between fibre content of the
lung and disease in East London asbestos factory workers. Br J Indust Med
1988;45:305.
294. Wagner JC, Pooley FD. Mineral fibres and mesothelioma. Thorax 1986;41:161.
295. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos
exposure in the Northwestern Cape Province. Br J Indust Med 1960;17:260.
296. Wagner MMF, Darke C, Coles RM, Evans CC. HLA-A and B antigen frequencies
and mesothelioma in relation to asbestos exposure. Br J Cancer 1983;48:727.
297. Walker C, Rutten F, Yuan X, et al. Wilms' tumor suppressor gene expression in rat
and human mesothelioma. Cancer Res 1994;54:3101.
298. Wanebo HJ, Martini N, Melamed MR, et al. Pleural mesothelioma. Cancer 1976;
38:2481.
299. Warren WH. The clinical manifestations and diagnosis of mesothelioma. In: Kittle
CF, editor. Mesothelioma: diagnosis and management. Chicago, IL: Year Book;
1987. p. 31.
300. Wasser L, Hunt M, Lerner H, et al. Phase II trial of PCNU in malignant mesothelioma.
An ECOG trial. Proc Am Soc Clin Oncol 1989;8:318.
301. Weiss SW, Tavassoli FA. Multicystic mesothelioma. An analysis of pathologic findings
and biologic behavior in 37 cases. Am J Surg Pathol 1988;12:737.
302. Whang-Peng J. 3p deletion and small cell lung carcinoma. Mayo Clin Proc 1989;
64:256.
303. Wirth PR, Legier J, Wright GL Jr. Immunohistochemical evaluation of seven monoclonal
antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.
Cancer 1991;67:655.
304. Whitaker D, Shilkin KB. The cytology of malignant mesothelioma in Western Australia.
Acta Cytol 1978;22:67.

Mesothelioma cancer research has been unable to produce an effective treatment modality for malignant mesothelioma.

Back to top